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Andreas Zeiher 17; On behalf of the BAMI Group†
1Centre for Cardiovascular Medicine & Devices, Queen Mary University of London, London EC1M 6BQ, UK; 2Hospital General Universitario Gregorio Mara~nón, Instituto de
Investigación Sanitaria del Hospital Gregorio Mara~nón, CIBERCV, Madrid, Spain; 3Cardiovascular Center, OLV Hospital Aalst, Aalst, Belgium 4KU, Leuven, Leuven, Belgium;
5Catholic University of the Sacred Heart, Rome, Italy; 6Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 7Department of Cardiac Surgery, Reparative Therapy
of the Heart, Vall d’Hebron Research Institute, University Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain; 8Queen Mary University of London,
London, UK; 9Kuopio University Hospital, Kuopio, Finland; 10University of Exeter, Exeter, UK; 11University Hospitals (UZ) Leuven, Belgium; 12University Hospital Brno and
Medical Faculty of Masaryk University, Brno, Czech Republic; 13Rigshospitalet and University of Copenhagen, Denmark; 14University College London, London, UK; 15Department
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Aims Bone marrow-derived mononuclear cell (BM-MNC) therapy may improve myocardial recovery in patients follow-




Originally an open-label, multicentre Phase III trial, BAMI was designed to demonstrate the safety and efficacy of
intracoronary infusion of BM-MNCs in reducing the time to all-cause mortality in patients with reduced left ven-
tricular ejection fraction (LVEF, <_45%) after primary angioplasty (PPCI) for ST-elevation AMI. Unexpectedly low re-
cruitment means the trial no longer qualifies as a hypothesis-testing trial, but is instead an observational study with
no definitive conclusions possible from statistical analysis. In total, 375 patients were recruited: 185 patients were
randomized to the treatment arm (intracoronary infusion of BM-MNCs 2–8 days after PPCI) and 190 patients to
the control arm (optimal medical therapy). All-cause mortality at 2 years was 3.26% [6 deaths; 95% confidence
interval (CI): 1.48–7.12%] in the BM-MNC group and 3.82% (7 deaths; 95% CI: 1.84–7.84%) in the control group.
Five patients (2.7%, 95% CI: 1.0–5.9%) in the BM-MNC group and 15 patients (8.1%, CI : 4.7–12.5%) in the control
group were hospitalized for heart failure during 2 years of follow-up. Neither adverse events nor serious adverse
events differed between the two groups. There were no patients hospitalized for stroke in the control group and
4 (2.2%) patients hospitalized for stroke in the BM-MNC group.
...................................................................................................................................................................................................
Conclusions Although BAMI is the largest trial of autologous cell-based therapy in the treatment of AMI, unexpectedly low re-
cruitment and event rates preclude any meaningful group comparisons and interpretation of the observed results.
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† See Supplementary material online, Appendix S6.
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Introduction
Despite more than two decades of pre-clinical and clinical research
testing the role of autologous cell-based therapies in the treatment of
cardiovascular disease, very few Phase III clinical trials have been con-
ducted. Although attempts were made to unify the experimental
approaches used1,2 (i.e. the type of cell, method, and timing of deliv-
ery), a multitude of Phase II trials have been published using differing
methodologies. The European Society of Cardiology’s Task Force for
cell-based therapies in cardiovascular disease created a Consortium
(listed in Supplementary material online, Appendix S1) to consolidate
this considerable pre-clinical research and design a definitive Phase III
clinical trial. The Consortium gained funding from the European
Commission to design and deliver BAMI: A Phase III clinical trial of au-
tologous cell-based therapies in the treatment of acute myocardial in-
farction (AMI).
Methods
The full final protocol can be found in Supplementary material online,
Appendix S2.
Study design
The autologous bone marrow cell therapy in acute myocardial infarction
trial (BAMI) was a multicentre, pan-European, investigator led, random-
ized, open-label trial co-ordinated by Queen Mary University of London.3
The trial was performed in accordance with the principles of the
Declaration of Helsinki. Approvals were obtained from local ethics com-
mittees and the pan-European Voluntary Harmonisation Procedure.
Funding was provided by the European Union FP7 programme following
a competitive application process. After a change in the regulatory proc-
esses, all sites contributed additional funding to cover the resultant short-
falls. The trial was designed and conducted by the BAMI Consortium and
was co-ordinated from the BAMI Trial Office in London.
Study population
Patients 18 years of age or older with an acute ST-elevation myocardial
infarction (as defined by the universal definition of AMI) undergoing acute
revascularization (i.e. either acute percutaneous coronary intervention
(PCI) within 24 h of symptom onset or thrombolysis within 12 h, followed
by acute PCI within 24 h after thrombolysis) were screened at investiga-
tional sites.
Potentially eligible patients were consented following their primary
PCI. The final eligibility criterion of <_45% left ventricular ejection fraction
(LVEF), based on previous studies suggesting a beneficial effect of
Graphical Abstract
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..cell therapies in patients with impaired cardiac function,4 was confirmed
2–6 days after the primary PCI by the central echocardiography core lab.
Patients with cardiogenic shock on admission, and those that developed
signs of heart failure following the primary PCI procedure, were
excluded. The full list of the inclusion and exclusion criteria can be found
in Supplementary material online, Appendix S2.
Figure 1 CONSORT diagram for patient flow in the BAMI trial.
























































































Bone marrow cell infusion
Eligible patients were randomized to the control arm or treatment arm in
a 1:1 ratio, which was stratified by country (summarized in Figure 1).
Patients in both arms underwent full medical optimization in alignment
with existing local protocols.
For patients randomized to the treatment arm, a bone marrow aspir-
ate was performed under local anaesthesia within 2–8 days of the primary
PCI. Fifty millilitres of bone marrow was drawn into 5 10 ml heparinized
syringes. The aspirates were immediately transported to a dedicated cell
processing facility where the bone marrow-derived mononuclear cells
(BM-MNCs) were isolated using a Ficoll density gradient as per the
t2cure method (Supplementary material online, Appendix S3). Following
separation, the BM-MNCs were re-suspended in X-Vivo 10 medium and
returned to the source site in a CryocyteVR bag. The BM-MNCs (range
25–500 106 as per protocol) were infused into the culprit coronary ar-
tery, that was treated with primary PCI at the index admission, using an
over-the-wire balloon that matched the vessel dimensions. Infusion used
the stop-flow technique: 3 min of balloon inflation with cells delivered
through the central lumen of the catheter, followed by 3 min of flow with
the balloon down.5 This cycle was repeated three times to deliver the full
10 mls of cells—3 stop-flow cycles of 3.3 ml each. Patients randomized to
the treatment arm were infused with BM-MNCs 2–8 days following the
primary PCI. Procedural anticoagulation was performed with bivalirudin
not heparin due to the possible interaction between the latter and the
BM-MNCs.6
Study outcomes
The initial study plan was to demonstrate a 25% reduction in all-cause
mortality at 2 years in patients treated with BM-MNCs. When the study
was conceived in 2011, contemporary data suggested an event (death)
rate of 12% in patients with reduced LVEF7,8,9 and a sample size of 3000
patients was calculated.3 The primary endpoint of the BAMI trial was the
time from randomization to all-cause mortality. The secondary endpoints
included time from randomization to cardiac mortality, the composite of
cardiovascular death or heart failure re-hospitalization, and the compos-
ite of re-hospitalization for repeat myocardial infarction, revasculariza-
tion, heart failure, implantable cardioverter-defibrillator (ICD), or stroke.
Safety endpoints included: adverse events (collected up to 6 months) and
serious adverse events, syncope, arrhythmia, neoplastic disease, and
bleeds at 2 years.
However, due to a combination of factors including a markedly
reduced number of patients with LVEF <_45%, a reduction in the mortality
in patients presenting with AMI (even with impaired left ventricular func-
tion), and a limitation on the duration of funding, the steering committee
re-issued the statistical analysis plan to present the data as observational
results (an ‘estimation’ trial10). This decision was scrutinized and
approved by the sponsor and regulatory authorities with a view that the
BAMI analysis would produce valuable indicators of effect size for future
studies.
All study patients returned for an onsite visit 30 days after hospital dis-
charge. Patients then underwent follow-up by telephone every 3 months
from randomization until the end of the trial hospital visit—each patient
was followed up for a minimum of 2 years. Endpoints were reported
throughout the follow-up period and were adjudicated by an independ-
ent Clinical Event Committee (CEC, Supplementary material online,
Appendix S6) blinded to the patient treatment allocation.
Statistical analysis
The original trial design was event-driven using existing registry data that
suggested a 12% mortality at 2 years in the control group,3 which would
be reduced to 9% (25% relative reduction, 1.355 hazard ratio) in the cell-
treated group. All patients recruited would complete a 2-year follow-up,
even if the trial was stopped prematurely. Using an alpha-spending func-
tion according to Lan-DeMets,11 450 events would have been required
to have 90% statistical power to detect treatment effect, requiring the re-
cruitment of 1500 patients to each arm. However, the aforementioned
markedly reduced recruitment and lower than expected event rates
meant that the trial’s statistical analysis would only be sufficient to report
effect size based on the reduced number of patients.
Kaplan–Meier curves have summarized the overall mortality by treat-
ment group and have not censored patients at 2 years, but have included
their entire follow-up (i.e. up to their time of death, study completion or
study termination). Event rates at 2 years are presented together with
their associated 95% confidence interval, obtained using a log(-log)-
transformation. The treatment effect is estimated by means of a hazard
ratio and its associated 95% confidence interval.
Cumulative incidence functions (CIFs) and their 95% CIs at 2 years
were calculated for the secondary endpoints and presented for each
randomized arm. The treatment effect is estimated by means of a hazard
ratio for the sub-distribution hazard of the event of interest using a Fine–
Gray regression model. The primary and secondary endpoints are ana-
lysed for Full Analysis Set (FAS i.e. intention to treat) and Per Protocol
Set (PPS).
The safety endpoints were analysed using the methods described for
the secondary efficacy endpoints. For the analysis of adverse events, CIFs
have been calculated up to 6 months as only serious events were
reported thereafter. Additional analyses were performed for the occur-
rence of any serious events within the Safety Set. For clarity, only the FAS
and Safety Set analyses are presented in the Results section.
The FAS included all patients who were randomized according to their
randomized allocation. The Safety Set included all patients according to
their actual treatment, i.e. untreated patients randomized to BM-MNC
were included in the control group.
All significance testing was two-sided and done at a significance level of
5%. However, due to the nature of the trial, with the aim of the trial being
the estimation of event rates and treatment effects, all significance testing
is of a purely exploratory nature. No adjustment was made to the signifi-
cance levels to account for multiple testing.
All analyses were performed using SAS version 9.4 and SAS/STAT ver-
sion 15.1 for Windows.
Results
Patient and procedural characteristics
From the trial’s start date (10 September 2013) to the last recruited
patient (25 October 2017), 518 patients with local LV function
thought to be <_45% were screened, from which 375 patients were
enrolled into the BAMI trial after core lab analysis confirmed an echo-
cardiographic LVEF <_45%. One hundred eighty-five patients were
randomized to the BM-MNC group and 190 patients to the control
arm. Thirty-seven sites were initiated in the study, out of which 28
contributed to recruitment and 23 delivered BM-MNC therapy (see
Supplementary material online, Appendix S4 for the list of sites). In the
BM-MNC group, 161 patients received cell therapy [median BM-
MNC infused 140  106, interquartile range (IQR) 138–340  106]
with 140 receiving cell therapy per protocol (see Supplementary ma-
terial online, Appendix S5 for the breakdown in discrepancy between
randomized and treated patients).
The baseline characteristics of all trial participants are presented in
Table 1. Both groups were well matched for age, ethnicity, and vital















..signs. Nominal differences in pre-morbid state were observed; the
treatment arm contained more patients with insulin-dependent dia-
betes (8.1% in the BM-MNC arm and 2.6% in the control arm), prior
history of myocardial infarction (11.4% and 5.3%), and previous per-
cutaneous revascularization (10.3% and 3.2%).
Primary PCI was performed in a timely manner from the onset of
chest pain in both groups [3.6 h (IQR 2.2–7.2) BM-MNC and 3.8 h
(IQR 2.3–7.6) control]. Likewise, the time from PCI to randomization
into the trial was similar for both groups [74 h (IQR 61–97) BM-
MNC and 73 h (IQR 57–97) control].
In both groups, the culprit lesion was most frequently located in
the left anterior descending coronary artery (86.5% in the BM-MNC
and 85.3% control group).
Echocardiographic ejection fraction as determined by the core lab
assessment prior to inclusion was 39% ± 5% in the BM-MNC and
39% ± 5% in the control group.
Endpoint analyses
The results are summarized in Table 2. There were six deaths in the
BM-MNC group [n = 185, estimated event rate 3.26%, 95%
....................................................................................................................................................................................................................
Table 1 Baseline characteristics for patients enrolled into BAMI
Baseline characteristic Statistic BM-MNC Control Total P-value
Total population N 185 190 375
Age [years] [n] Mean (SD) [185] 59 (11) [190] 60 (11) [375] 59 (11) 0.29
Female (%) n/N (%) 30/185 (16.22) 43/190 (22.63) 73/375 (19.47) 0.12
Race
White n/N (%) 165/185 (89.19) 179/190 (94.21) 344/375 (91.73) 0.15
Black n/N (%) 3/185 (1.62) 4/190 (2.11) 7/375 (1.87)
Asian n/N (%) 12/185 (6.49) 6/190 (3.16) 18/375 (4.80)
Other n/N (%) 5/185 (2.70) 1/190 (0.53) 6/375 (1.60)
Vital signs
Systolic BP [mmHg] [n] Mean (SD) [184] 114 (15) [190] 113 (18) [374] 114 (17) 0.63
Diastolic BP [mmHg] [n] Mean (SD) [183] 69 (10) [190] 69 (12) [373] 69 (11) 0.79
Heart rate [b.p.m.] [n] Mean (SD) [184] 77 (13) [190] 78 (12) [374] 77 (13) 0.58
Killip class
1 n/N (%) 140/176 (79.55) 136/179 (75.98) 276/355 (77.75) 0.28
2 n/N (%) 32/176 (18.18) 38/179 (21.23) 70/355 (19.72)
3 n/N (%) 2/176 (1.14) 5/179 (2.79) 7/355 (1.97)
4 n/N (%) 2/176 (1.14) 0/179 (0.00) 2/355 (0.56)
Hypertension n/N (%) 83/185 (44.86) 94/190 (49.47) 177/375 (47.20) 0.41
Hypercholesterolaemia n/N (%) 69/185 (37.30) 72/190 (37.89) 141/375 (37.60) 0.92
Insulin-dependent diabetes n/N (%) 15/185 (8.11) 5/190 (2.63) 20/375 (5.33) 0.02
Non-insulin-dependent diabetes n/N (%) 23/185 (12.43) 17/190 (8.95) 40/375 (10.67) 0.32
Current smoker n/N (%) 79/185 (42.70) 76/190 (40.00) 155/375 (41.33) 0.60
Prior smoker n/N (%) 33/185 (17.84) 41/190 (21.58) 74/375 (19.73) 0.39
Prior MI n/N (%) 21/185 (11.35) 10/189 (5.29) 31/374 (8.29) 0.04
Prior percutaneous revascularization n/N (%) 19/185 (10.27) 6/189 (3.17) 25/374 (6.68) 0.01
CABG n/N (%) 0/185 (0.00) 2/189 (1.06) 2/374 (0.53) 0.50
Stroke n/N (%) 5/185 (2.70) 3/189 (1.59) 8/374 (2.14) 0.50
Renal insufficiency n/N (%) 8/185 (4.32) 5/189 (2.65) 13/374 (3.48) 0.41
Malignancy n/N (%) 5/185 (2.70) 13/189 (6.88) 18/374 (4.81) 0.09
Time intervals
Time from onset to PCI [h] [n] Median (Q1; Q3) [176] 3.6 (2.2; 7.2) [187] 3.8 (2.3; 7.6) [363] 3.7 (2.3; 7.5) 0.64
Time from onset to randomization [h] [n] Median (Q1; Q3) [179] 81 (66; 106) [187] 80 (61; 103) [366] 81 (63; 103) 0.32
Time from PCI to randomization [h] [n] Median (Q1; Q3) [181] 74 (61; 97) [190] 73 (57; 97) [371] 74 (57; 97) 0.28
Location of culprit lesion
LM n/N (%) 2/185 (1.08) 4/190 (2.11) 6/375 (1.60) 0.69
LAD n/N (%) 160/185 (86.49) 162/190 (85.26) 322/375 (85.87) 0.77
CX n/N (%) 6/185 (3.24) 9/190 (4.74) 15/375 (4.00) 0.60
RCA n/N (%) 17/185 (9.19) 15/190 (7.89) 32/375 (8.53) 0.71
Unknown n/N (%) 0/185 (0.00) 0/190 (0.00) 0/375 (0.00)
Core Lab LVEF [%] [n] Mean (SD) [185] 39 (5) [190] 39 (5) [375] 39 (5) 0.24






confidence interval (CI): 1.48–7.12%] and seven deaths in the control
group (n = 190, 3.82%, 95% CI: 1.84–7.84% control) (Figure 2A).
There were three cardiac deaths in the BM-MNC group (1.63%, 95%
CI: 0.45–4.37%) and four cardiac deaths in the control group (2.18%,
95% CI: 0.72–5.15%). Kaplan–Meier curves illustrate the temporal oc-
currence of the composite secondary endpoints in Figure 2C and D.
....................................................................................................................................................................................................................
Table 2 Summary of results of BAMI for the full analysis and safety sets
















Primary endpoint (Survival analyses
performed)
Full analysis set (N) 185 190
All-cause mortality 6 (3.3%:1.5 -7.1%) 7 (3.8%:1.8–7.8%) 0.85 (0.29–2.53) 2 years
Secondary efficacy endpoints
(Competing risk analyses performed)
Cardiac mortality 3 (1.6%: 4 (2.2%: 0.75 2 years
0.5–4.4%) 0.7–5.2%) (0.17–3.32)
Cardiovascular death or Re-hospitaliza-
tion due to heart failure
9 (4.9%: 18 (9.7%: 0.48 2 years
2.4–8.7%) 6.0–14.5%) (0.22–1.06)
Re-hospitalization due to re-myocardial
infarction, revascularization, heart
failure, implantable cardioverter-
defibrillator (ICD) or stroke
Breakdown:
31 (16.9%: 40 (21.5%: 0.72 2 years
11.9–22.7%) 15.9–27.7%) (0.45–1.14)
• Re-hospitalization due to re-myocar-
dial infarction
5 (2.7%: 7 (3.8%: 0.701 2 years
1.0–5.9%) 1.7–7.3%) (0.22–2.19)
• Re-hospitalization due to
revascularization
13 (7.1%: 14 (7.5%: 0.902 2 years
4.0–11.4%) 4.3–11.9%) (0.43–1.91)
• Re-hospitalization due to heart failure 5 (2.7%: 15 (8.1%: 0.332 2 years
1.0–5.9%) 4.7–12.5%) (0.12–0.88)
• Re-hospitalization due to ICD implant 10 (5.4%: 16 (8.7%: 0.614 2 years
2.8–9.4%) 5.2–13.4%) (0.28–1.35)
• Re-hospitalization due to stroke 4 (2.2%: 0 (0.0%) Not calculable 2 years
0.7–5.1%)
Secondary safety endpoints (Competing
risk analyses performed)
Safety set (N) 161 214
Any adverse events 101 (62.8%: 116 (54.9%: 1.20 6 months
54.8–69.8%) 47.9–61.4%) (0.92–1.55)
Any serious adverse events 57 (41.5%: 78 (60.9%: 0.96 5 years
31.8–50.9%) 40.7–76.1%) (0.68–1.36)
Re-hospitalization due to stroke* 7 (6.5%: 1 (1.1%: 9.17 5 years
2.4–13.4%) 0.1–5.5%) (1.14–73.47)
Bleeds 28 (18.1%: 29 (14.2%: 1.29 5 years
12.4–24.6%) 9.8 -19.4%) (0.77- 2.16)
Neoplastic disease 7 (6.6%: 8 (5.4%: 1.14 5 years
2.7–13.0%) 2.3–10.3%) (0.41 -3.12)
Syncope 8 (6.5%: 7 (4.5%: 1.48 5 years
2.8–12.3%) 1.7–9.6%) (0.54–4.06)
Arrhythmias (atrial fibrillation and ven-
tricular tachycardia)
9 (6.3%: 19 (9.6%: 0.60 5 years
3.0–11.2%) 6.0–14.4%) (0.27–1.31)
*Rehospitalization due to stroke is an efficacy endpoint, but additional safety analysis has been performed.
































Analysis of the secondary endpoints (FAS) demonstrated that five
patients in the BM-MNC group were re-hospitalized due to heart fail-
ure (2.7%, 95% CI: 1.0–5.9%) and 15 patients (8.1%, CI: 4.7–12.5%) in
the control group (Table 2). Four patients in the BM-MNC group
(2.2%, 95% CI: 0.7–5.1%) and 0 patients in the control group were
hospitalized due to stroke (Table 2). Site-based assessment of each
individual stroke hospitalization (which occurred 1–19 months
post-cell infusion) did not suggest that these events were related to
BM-MNC therapy.
Figure 3 illustrates cumulative event rates in both groups for any
adverse event (Figure 3A), any serious adverse event (Figure 3B), re-
hospitalization for stroke (Figure 3C), and the occurrence of bleeding
(Figure 3D).
Discussion
Given the low recruitment and event rates, BAMI does not qualify for
assessing the efficacy of the administration of autologous BM-MNCs
on all-cause mortality, nor can it be viewed as a hypothesis-testing
trial in patients with successfully re-perfused AMI and depressed LV
function 2–6 days post-reperfusion therapy. Consequently, no group
comparisons are possible and the data presented are descriptive in
nature. However, since BAMI is the largest trial investigating the use
of autologous BM-MNC administration in AMI, we believe that the
results do provide insights into the future of new therapeutics in the
treatment of AMI, and the challenges of designing and conducting tri-
als of autologous BM-MNC-based therapies in AMI.
Firstly, one of the most striking observations is the trial’s very low
mortality rate. When the study was conceived in 2011 existing regis-
tries suggested that in patients with an LVEF <_45% post-reperfusion
therapy, an all-cause mortality of 12% at 2 years could be
expected3,7,9 reflecting the result of primary angioplasty services that
were in evolution during the preceding years. Moreover, the
REPAIR-AMI trial, performed in 2004 and 2005, showed that the
beneficial effects of BM-MNC administration on clinical outcome
(mortality and re-hospitalization for heart failure) was entirely
confined to patients with a baseline LVEF <_45%. Finally, in BAMI,
all-cause mortality was chosen as the primary endpoint in order to
mitigate any effects of the open-label trial design without a placebo
Figure 2 Kaplan–Meier curves showing primary and secondary endpoint results in the BAMI trial: (A) Primary endpoint—all-cause mortality up to
2 years (full analysis set). (B) Secondary endpoint—cumulative incidence functions for cardiac death up to 2 years (full analysis set). (C) Secondary
endpoint—cumulative incidence functions for cardiovascular death or re-hospitalization due to heart failure up to 2 years (full analysis set). (D)
Secondary endpoint—cumulative incidence functions for re-hospitalization due to repeat myocardial infarction, revascularization, heart failure,
implantable cardioverter-defibrillator, or stroke up to 2 years (full analysis set).





























.control group, as the intracoronary instrumentation for infusion of a
placebo preparation was previously criticized as it may increase event
rates in the placebo group and, thereby, skew the results towards the
treatment arm. The trial’s very low all-cause mortality (composite of
3.5%) demonstrates the overwhelmingly successful implementation
of primary angioplasty across the 28 recruiting sites in 10 European
countries, as well as the effectiveness of concomitant medical ther-
apy. Likewise, the difficulty in identifying patients with an ejection frac-
tion <_45% also points to the success in improved management of
myocardial infarction in BAMI sites. Thus, if all-cause mortality is the
primary outcome of a trial of new therapeutics for myocardial infarc-
tion, the sample size of enrolled patients will need to be much larger
(over 10 000 patients, using a mortality rate of 3.5%). This would like-
ly make the trial futile based on cost and logistics. This suggests that
future studies will need careful consideration with respect to target
population and the use of composite endpoints to meet regulatory
approval.
Notwithstanding all these limitations, the results of the present
study illustrate that besides the very low mortality rates, re-
hospitalization for heart failure occurs very infrequently during
2 years of follow-up, even in patients with a mean LVEF of 39% within
2–6 days of successful acute PCI for AMI.
Thus, for future trials, the logistical and regulatory considerations
currently required to administer cell-based products,12 even if effi-
cacy is shown, could only be offset by seeing a dramatic beneficial ef-
fect of BM-MNC therapy. Given the low event rate seen in BAMI, the
number of patients needed to demonstrate a significant treatment ef-
fect, and the logistical costs involved, it is suggested that future trials
would be prohibitively expensive. It is important to consider that the
largest advance in the treatment of AMI in recent years has been pri-
mary angioplasty, which was affected by a change in clinical pathways,
not the discovery of a new therapeutic. Whether BM-MNC therapy
has a role in other forms of cardiac disease (e.g. heart failure and re-
fractory angina13,14) remains to be seen.
The BAMI trial was pivotal due to several important considera-
tions. This was the first attempt at a Phase III study of BM-MNC ther-
apy in the treatment of AMI delivered by an academic Consortium.
The Consortium achieved an agreement on a definitive trial design
Figure 3 Kaplan–Meier curves showing safety and efficacy endpoints in the BAMI trial. (A) Cumulative incidence functions for any adverse event
up to 6 months (safety set). (B) Cumulative incidence functions for serious adverse events up to 5 years (trial end) (safety set). (C) Cumulative inci-
dence functions for re-hospitalization due to stroke up to 5 years (trial end) (safety set). (D) Cumulative incidence functions for bleeding up to 5 years
(trial end) (safety set).
























































































based on existing Phase II trial data collected over the preceding dec-
ade (which included patient selection, the processing of cells and the
timing of infusion) and took into consideration the various changes in
regulatory approvals that occurred between the trial’s planning and
completion. The BAMI trial most closely followed the design and
methodologies used in the Phase II REPAIR-AMI study, including the
delivery of the same order of magnitude of cells. REPAIR-AMI dem-
onstrated improved clinical outcomes including mortality and re-
hospitalization for heart failure in patients with reduced LVEF during
long-term follow-up after AMI, but was performed in 2004 and
2005.15 Furthermore, meta-analyses demonstrated a signal towards
reduced mortality and morbidity following BM-MNC therapy16,17;
this was in the context of clinical trials of cell-based therapies in
patients with AMI which initially did not show dramatic changes in
LVEF, but went on to show significant reductions in mortality.18
The trial’s conduct highlighted several important difficulties regard-
ing the regulatory processes surrounding the use of cell-based prod-
ucts in large multicentre, pan-European studies. Although ultimately
the logistical issues were solved, the cost in time and money signifi-
cantly impacted the success of the trial.19
In conclusion, while BAMI cannot provide any definitive answers
regarding the effect of BM-MNC therapy on all-cause mortality in
AMI patients due to the significant under recruitment, it did demon-
strate that autologous cell-based therapy can be delivered following
AMI in multiple sites across Europe. The very low 2-year all-cause
mortality rate, and the small number of patients developing post-
infarction heart failure within 2 years following primary angioplasty
for AMI provides useful information regarding the challenges and diffi-
culties involved in future trials of cell-based therapies.
Supplementary material
Supplementary material is available at European Heart Journal online.
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